Androgen biosynthesis [testosterone production in the Leydig cells of the testis under luteinizing hormone (LH) control and 5a-dihydrotestosterone (5a-DHT) production under local control in peripheral tissues] is essential for sex determination and mature sexual development in men. In the absence of these androgens, hypogonadism and pseudohermaphroditism occur [1, 2] . As men age, there is a slow decline in circulating testosterone, which can lead to deleterious effects (e.g., loss of libido, osteoporosis, and loss of muscle mass). These are symptoms of the so-called 'andropause' that do not affect all men equally [3 ,4].
Purpose of review
To summarize recent advances in androgen biosynthesis and metabolism in peripheral tissues (e.g., liver and prostate) and how these can be exploited therapeutically.
Recent findings
Human liver catalyzes the reduction of circulating testosterone to yield four stereoisomeric tetrahydrosteroids. Recent advances have assigned the enzymes responsible for these reactions and elucidated their structural biology. Data also suggest that for 5a-dihydrotestosterone (5a-DHT), conjugation reactions (phase II) may precede ketosteroid reduction (phase I) reactions. Human prostate is the site of benign prostatic hyperplasia and prostate cancer, which occur in the aging male. Although the importance of local androgen biosynthesis in these diseases is accepted, recent advances have identified enzymes that regulate ligand access to the androgenreceptor; a 'backdoor pathway' to 5a-DHT that does not require testosterone acting as an intermediate; and the finding that castrate-resistant prostate cancer (CRPC) has undergone an adaptive response to androgen deprivation, which involves intratumoral testosterone and 5a-DHT biosynthesis that can be targeted using inhibitors of (CYP17hydroxylase/17,20-lyase), aldo-keto reductase 1C3, and 5a-reductase type 1 and type 2. Summary Enzyme isoforms responsible for the biosynthesis and metabolism of androgens in liver and prostate have been identified and those responsible for the biosynthesis of androgens in CRPC can be therapeutically targeted. 5a-reductase type 1 (SRD5A1) or steroid 5b-reductase (AKR1D1) to yield 5a-DHT and 5b-DHT, respectively [2, 7] . Each of these dihydrosteroids are further reduced by 3a-hydroxysteroid dehydrogenase or 3b-hydroxysteroid dehydrogenase (HSDs) to yield four stereoisomeric tetrahydrosteroids, that is, 5a-androstane-3a, 17b-diol (3a-diol), 5a-androstane-3b,17b-diol (3b-diol), 5b-androstane-3a,17b-diol, and 5b-androstane-3b,17bdiol ( Fig. 1 ). It is now recognized that human liver contains four aldo-keto reductase (AKR) isoforms (AKR1C1-AKR1C4), which are NADPH-dependent ketosteroid reductases. These enzymes display different ratios of 3a-/3b-HSD activity [8, 9] and couple with either SRD5A1 or AKR1D1 to produce the four isomeric products observed. For example, SRD5A1 and AKR1C1 couple to produce 3b-diol and SRD5A1 and AKR1C2 couple to produce 3a-diol [9] .
Until recently, no structural information existed on any mammalian steroid double-bond reductase. Recently, the structures of several AKR1D1-NADP þ -steroid (testosterone, progesterone, cortisol, 5b-dihydroprogesterone, finasteride) ternary complexes were reported [10 ,11,12 ,13] . This enzyme has the (a/b) 8 -barrel structural motif shared by the AKR superfamily and contains three large loops at the back of the structure that determine substrate specificity ( Fig. 2a ). The cofactor-binding site is highly conserved within the superfamily and straddles the lip of the barrel in an extended anticonformation that determines 4-proR-hydride transfer to C5 of the steroid. By conducting hydride transfer to the b-face of the steroid, the A/B cis-ring junction is introduced and a 90 8 bend into the planar steroid structure is generated ( Fig. 1) . This AKR has a substitution in its catalytic tetrad where E120 replaces a histidine. The structure reveals that this substitution allows the steroid substrate to penetrate further into the active site so that the hydride donor (NADPH) and C5 of the steroid are optimally aligned. In addition, the side chain of the E120 is in a fully protonated anticonformation, which forms hydrogen bonds with the C3-ketone of the steroid and, in concert with the catalytic tyrosine (Y58), promotes enolization of the ketosteroid (Fig. 2b) . Thus, the mechanism of steroid double-bond reduction has been revealed for the first time.
Finasteride (a selective mechanism-based inactivator of SRD5A2) is a competitive inhibitor of 5b-reductase K i ¼ 2.1 mmol/l. However, finasteride is not a mechanism-based inactivator of AKR1D1, and the structure of the AKR1D1-NADP þ -finasteride complex explains why this is the case [12 ] . The NADPH is on the wrong side of the steroid pocket in AKR1D1 and, thus, reduction The reductive enzymes responsible for the metabolism of testosterone to its four stereoisomeric tetrahydrosteroids are shown (genes are italicized). The inset shows the preferred pathway of 5a-DHT metabolism with glucuronidation (a phase II reaction) preceding 3-ketosteroid reduction (a phase I reaction). AKR1C4 is shown preferentially reducing 5a-DHTG to 3a-diol-17G, as it has the highest catalytic efficiency for this reaction among the
of the D 1,2 -ene of finasteride observed in SRD5A2 to produce a bisubstrate analog is not possible. The K i value of finasteride for AKR1D1 is only one order of magnitude higher than that observed for SRD5A1, suggesting that high doses of this drug would inhibit both enzymes. In this instance, finasteride would inhibit its own metabolism. 5b-Pregnanes produced by AKR1D1 are ligands for the orphan nuclear receptors pregnane X receptor and constitutive androstane receptor, which when activated induce CYP3A4 [14, 15] . This cytochrome P450 isoform is the major enzyme involved in finasteride metabolism [16] .
The route of hepatic androgen metabolism so far described leads to tetrahydroandrostanes, which are conjugated as either glucuronides or sulfates for excretion, that is, reduction of the ketosteroid (phase I reactions) precedes conjugation reactions of the alcohol (phase II reactions). In recent studies, evidence for the reverse sequence was found to exist [17 ] . AKR1C1-AKR1C4, which reduces 5a-DHT and 5b-DHT to their corresponding 3a-diol and 3b-diol, was found to have high catalytic efficiencies toward 5a-DHT-17b-glucuronide or 5b-DHT-17bsulfate. The products of the reactions were verified by liquid chromatography-mass spectrometry (LC-MS). Interestingly, although uridine glucuronsyl transferase (UGT)2B7 preferentially catalyzes the 3 0 -OH glucuronidation of 3a-diol and is highly expressed in liver [18] , no 3 0 -glucuronide is formed in the circulation, suggesting that the dominant pathway is conjugation at the 17b-position followed by reduction of the 3-ketone [17 ] (Fig. 1, inset) . Others have proposed that steroid metabolism could occur on steroid conjugates [19, 20] , but these recent studies revive this issue with strong supporting data.
Prostate androgen biosynthesis and metabolism
BPH and prostate cancer are two separate diseases. The former originates in the transitional zone, where outgrowth of the stromal and epithelial cells leads to obstruction of the urinary bladder and difficulty in voiding the urine. By contrast, prostate cancer is a disease of the peripheral zone (outer prostate) and aggressive disease can metastasize into the adjacent lymph glands and bone. Both are dependent on intratumoral conversion of testosterone (K d ¼ 10 À9 mol/l for AR) to the higher-affinity ligand 5a-DHT (K d ¼ 10 À11 mol/l for AR) and can be treated by blocking 5a-DHT synthesis. For this approach to be effective, a detailed knowledge of androgen biosynthesis in both disease states is required with the understanding that there may be paracrine influences between epithelial and stromal cells.
The route to 5a-DHT production in the prostate starting from circulating dihydroepiandrosterone (DHEA) is shown in Fig. 3 . Major progress in this area has led to the precise annotation of the enzyme isoforms involved in the process as follows: (i) DHEA is converted to D 4 -androstene-3,17-dione by 3b-HSD/ketosteroid isomerase type 1 and type 2 (HSD3B1 and HSD3B2) [21, 22] ; (ii) D 4 -androstene-3,17-dione is reduced to testosterone by 17b-HSD type 5 (AKR1C3) [23] [24] [25] [26] ; (iii) testosterone is reduced to 5a-DHT by both 5a-reductase type 1 and type 2 (SRD5A1 and SRD5A2), where the type 2 enzyme plays the more dominant role [2, 27] ; (iv) 5a-DHT is reduced by 3a-HSD type 3 (AKR1C2) to produce 3a-diol and by 3(20a)-HSD (AKR1C1) to produce 3b-diol [9, 23, 28, 29] ; and (v) 17b-hydroxysteroids can be conjugated by glucuronidation by UGT2B15/17 [18, 30 ] .
Several features are worth mentioning. First, the pathway from DHEA is emphasized because in the aging men the New frontiers in androgen biosynthesis and metabolism Penning 235 Figure 2 Structure and mechanism of human steroid 5breductase (AKR1D1) (a) (a/b) 8 -Barrel structure of an AKR1D1-NADP þ binary complex. NADP þ is in a stick presentation, a water molecule (red ball) is hydrogen bonded to Y58 and E120 of the catalytic tetrad that also contains (D53 and K87); and the three loops A, B, and C, which comprise the steroidbinding site are in blue. (b) Catalytic mechanism of steroid double bond reduction.
influence of adrenal androgens acting as precursors becomes pronounced. Second, AKR1C3 is the peripheral 17-ketosteroid reductase responsible for testosterone production. It has been shown to be expressed in prostate at the RNA, protein, and functional level [24, 25, 31] . The enzyme is more highly expressed in epithelial cells than in stromal cells and is upregulated in the prostate cancer [23] . By contrast, although Leydig cell-specific 17b-HSD type 3 (HSD17B3) transcripts have been detected in the prostate, its role in testosterone production in this tissue remains to be elucidated [32 ] . Third, the inability of finasteride to reduce prostatic volume by more than 30% and intraprostatic 5a-DHT levels by more than 90% suggests that 5a-DHT stillformsin sufficientamounts to sustain prostate size [33] . Fourth, AKR1C2 is the dominant 3-ketosteroid reductase that will convert 5a-DHT (K d ¼ 10 À11 mol/l for AR) to 3a-diol (K d ¼ 10 À6 mol/l for AR) and will prevent 5a-DHT from binding to its receptor [9, 23, 29] . Fifth, the highly related AKR1C1 (98% sequence identity) instead converts 5a-DHT to 3b-diol, where 3b-diol is a proapototic ligand for estrogen receptor b [9, 34, 35] .
Studies in castrate dogs [36] , the tamar wallaby [37, 38] , and humans [39] all support the back conversion of 3a-diol to 5a-DHT with growth consequences for the prostate. Five different short-chain dehydrogenase genes (HSD17B10, HSD17B6, RDH5, DHRS9, and RODH4) have been invoked as being the oxidative 3a-HSDs responsible for this back conversion. However, detailed kinetic analysis using mammalian expression systems and expression profiling have provided unequivocal evidence that the enzyme responsible is 'RoDH-like 3a-HSD' (HSD17B6) [40] . Remarkably, HSD17B6 is more highly expressed in stromal than in epithelial cells, providing a paracrine influence on the later. These data beg the question as to the circulating source of 3a-diol. Recently, a 'backdoor pathway' to 5a-DHT was proposed, starting with adrenal steroidogenesis to generate progesterone [41, 42] . In this pathway, progesterone is converted to 17a-hydroxy-progesterone by CYP17a-hydroxylase/ 17,20 lyase and then reduced by SRD5A1 to yield 5a-pregnane-17a-ol-3,20-dione. This is then reduced by AKR1C2 to yield 5a-pregnane-3a,17a-diol-20-one. Subsequent reaction by CYP17a-hydroxylase/17,20lyase would produce androsterone, which is then reduced by AKR1C3 to 3a-diol. Thus, a new molecular switch that controls ligand access to the AR has been identified as AKR1C2, which reduces 5a-DHT to 3a-diol (in epithelial cells), and HSD17B6, which oxidizes 3a-diol back to 5a-DHT (in stromal cells) [43, 44 ] .
Targeting the androgen axes in prostate disease
Finasteride was originally used to treat BPH, but despite the beneficial affects on reducing prostatic volume and 236 Androgens Figure 3 Androgen biosynthesis in the prostate Traditional pathway converting DHEA to 5a-DHT is shown in blue. Arrows and genes in blue show altered expression in CRPC. Arrows and genes in red show the molecular switch that regulates ligand access to the AR. AKR1C2 is also overexpressed in CRPC. Arrows in gray show de-novo routes to DHEA and D 4 -androstene-3,17-dione that may contribute to adaptive androgen biosynthesis in CRPC. Open orange arrows show the backdoor pathway to 5a-DHT. AR, androgen-receptor; CRPC, castrate-resistant prostate cancer; DHEA, dihydroepiandrosterone; 5a-DHT, 5a-dihydrotestosterone.
intraprostatic 5a-DHT levels symptomatic relief was disappointing [33] . This led to the concept that dutasteride, a dual SRD5A1 and SRD5A2 inhibitor, would provide greater benefit [45 ] . In a side-by-side comparison of finasteride and dutasteride, symptomatic relief seems comparable [33] . Although compounds such as terazosin and tamsulosin (a-adrenergic receptor antagonists) may be superior compounds to increase urine flow [46] , they do not halt the natural progression of the disease that can be achieved with 5a-reductase inhibitors.
Androgen ablative therapy is a major treatment for prostate cancer. The disease can be treated by surgical castration and prostatectomy or by the combined use of a LH-releasing hormone (RH) agonist (leuprolide) and an AR antagonist (bicalutamide or flutamide). Leuprolide blocks LH production at the level of the anterior pituitary and reduces circulating testosterone levels to those seen in castrated men (<0.2 ng/ml) [47] . By contrast, bicalutamide prevents binding of 5a-DHT to the AR with an EC 50 ¼ 160 nmol/l [48 ] . Dual inhibition of both SRD5A1 and SRD5A2 with dutasteride may also be effective in preventing or delaying the growth of prostate cancer and is the focus of the ongoing 4-year REduction by DUtasteride of prostate Cancer Events (REDUCE). Irrespective of the treatment regimen, in about 30-40% of cases, the cancer can re-emerge (2-3 years later) with a telltale increase in prostatic-specific antigen (PSA). This recurrent cancer has been described as castrate-resistant prostate cancer (CRPC). Consensus has built that CRPC is not androgen-independent and that both adaptive responses in AR signaling [49 ,50,51] and increased dependence on intratumoral androgen biosynthesis [32 ,52 ,53] may drive the disease and bypass the form of castration used. Recently, a phase I/II clinical trial of abiraterone acetate (a CYP17a-hydroxylase/17,20-lyase inhibitor) in advanced CRPC was shown to reduce PSA levels and bone metastases in a dramatic fashion [54 ,55 ] . These studies added weight to the importance of intratumoral formation of androgens [54 ] . Abiraterone acetate would block not only the adrenal production of DHEA but also de-novo synthesis of DHEA in the prostate, and together these mechanisms would prevent the formation of testosterone and 5a-DHT in the tumor.
Evidence for the importance of intratumoral formation of androgens in CRPC has come from studies in patients and xenograft models. Affymetrix microarray analysis and confirmatory real-time PCR in both primary prostate tumors and 'androgen-independent prostate cancer' showed the following fold increases in gene expression in the latter disease: AR (5.8); HSD3B2 (1.8); AKR1C3 (5.3); SRD5A1 (2.1); SRD5A2 (0.54); AKR1C2 (3.4); AKR1C1 (3.1); and UGTB15 (3.5). The increase in AKR1C3 expression was also confirmed by immuno-histochemistry [53] . In a subsequent study, levels of testosterone and 5a-DHT were measured in prostate cancer and CRPC using stable-isotope dilution LC-MS and this was related to a transcript level. Interestingly, prostate cancer gave 0.23 ng/g testosterone and 2.75 ng/g 5a-DHT; but in CRPC, the levels were reversed to 0.74 ng/g testosterone and 0.25 ng/g 5a-DHT. These changes were reflected by increases in the transcripts for CYP17A1, HSD3B1, and AKR1C3 and decreases in SRD5A2 [32 ] . Taken together, there seems to be an adaptive response for CRPC to synthesize their own androgens and that there may be a shift toward the production of testosterone over 5a-DHT.
The dependence of CRPC on intratumoral androgens has also been modeled in LNCaP (AR-positive cancer cell line) xenografts in castrated immunodeficient mice [52 ,56 ,57] . A caveat of this model is that CYP17ahydroxylase/lyase is not expressed in the murine adrenal gland and these tumors may be under additional selection pressure to produce their own androgens. Nevertheless, ex-vivo experiments on the recurrent tumors provided evidence of the conversion of [ 14 C]-acetate into 5a-DHT and the conversion of [ 3 H]-progesterone into pregnane intermediates in the 'backdoor' pathway to 5a-DHT ( Fig. 3) [52 ,56 ] . These experiments have been recapitulated to show that testosterone production is accompanied by increases in StaR (steroidogenic acute regulatory protein) and side-chain cleavage enzyme (CYP11A1), which suggest that de-novo synthesis from cholesterol could be occurring [52 ,58] . In other studies on the LNCaP xenograft model, a co-ordinated response to increase cholesterol influx and cholesterol biosynthesis was observed (including altered expression of lowdensity lipoprotein receptor, scavenger receptor class B type I, 3-hydroxy-3-methyl-glutaryl-CoA reductase, ACT1,2, and ABCA1 proteins) [56 ] . Thus, CRPC can find a way to produce its own androgens.
The dramatic response to abiraterone acetate suggests a role for targeting androgen biosynthesis in CRPC. Because this drug inhibits CYP17a-hydroxylase/17,20-lyase, there are concerns that this will have the unintended consequence to cause the accumulation of the mineralocorticoid desoxycorticosterone in the adrenal. This will be exacerbated by the lack of cortisol to cause feedback inhibition of adrenocorticotropic hormone at the level of the anterior pituitary. Excess production of mineralocorticoid is currently prevented by the co-administration of dexamethasone [55 ] . The success of abiraterone acetate has led to the development of both steroidal and nonsteroidal inhibitors of this enzyme [59, 60 ] . One such compound VN/124-1 not only inhibits the target enzyme but also increases the rate of AR degradation [60 ] . An alternative attractive target for CRPC, which is downstream from CYP17, is AKR1C3, which catalyzes the final step in prostate testosterone biosynthesis. Compounds that target this enzyme would not have to be coadministered with dexamethasone. Indomethacin and indomethacin analogs that do not inhibit COX-1 and COX-2 are lead compounds in targeting AKR1C3 [61 ] . Importantly, these compounds do not inhibit the highly related AKR1C1 and AKR1C2. All these AKR1C isoforms are inhibited by the N-phenylantharnilic acids including flufenamic acid [62] . Recently, flufenamic acid analogs were reported to be AR antagonists [63] . Thus, another strategy for the treatment of CRPC would be to develop flufenamic acid analogs that target AKR1C3 and AR but leave AKR1C1 and AKR1C2 unaffected.
Conclusion
Reductive androgen metabolism in extragonadal tissues is now understood relative to the genes and enzyme isoforms involved. In liver, a case can be made for reduction occurring after phase II conjugation reactions. In CRPC, adaptive local androgen biosynthesis may surmount androgen deprivation and the enzymes involved may be drug targets for advanced disease.
